ON DEMAND WEBINAR
Duration: 27 minutes​

Semaglutide and other glucagon-like-peptide-1 (GLP-1) receptor agonists have revolutionized the treatment for Type 2 diabetes and, now with a Food and Drug Administration extension, for chronic weight management as well. Despite the drug’s proven efficacy, users have experienced significant heterogeneity in the degree of weight loss, with contributing factors remaining unclear. In this research webinar and Q&A, learn how weight loss with semaglutide is influenced by traditional metabolic risk factors and genetic variants associated with body mass index (BMI) changes. Key learnings include: 

• Identifying demographic and metabolic factors associated with weight-loss trajectories over 12 months after initiation of semaglutide.
• Evaluating the effect of an established BMI polygenic score.
• Discovering Helix’s precision clinical research network and clinico-gneomic virtual registry for patients treated with a GLP-1 agonist.

SPEAKERS

Dr. Matt Levy
Senior Research Scientist
Helix
 

Jay Shah
Marketing Director, Life Sciences
Helix